Uncovering the Role of Anmeidan against Atherosclerosis from Integrated Network Pharmacology and Pharmacological Experiments

Yuting Zheng; Jianxiang Wang; Chengcheng Pan; Jihong Song; Xingyue Li; Wenjing Ta; Wen Lu

doi:10.2174/0113862073281925240417062009

Uncovering the Role of Anmeidan against Atherosclerosis from Integrated Network Pharmacology and Pharmacological Experiments

Comb Chem High Throughput Screen. 2024 Apr 25. doi: 10.2174/0113862073281925240417062009. Online ahead of print.

Authors

Yuting Zheng¹, Jianxiang Wang¹, Chengcheng Pan¹, Jihong Song¹, Xingyue Li¹, Wenjing Ta¹, Wen Lu¹

Affiliation

¹ School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.

PMID: 38676497
DOI: 10.2174/0113862073281925240417062009

Abstract

Background: Atherosclerosis (AS) is the leading cause of mortality in elderly individuals worldwide. Anmeidan (AMD) is a Traditional Chinese Medicine (TCM) formula composed of many herbs, many of which have been accepted for treating AS. This study aimed to explore whether AMD can inhibit the progress of AS and its possible mechanism.

Methods: ApoE-/- mice were used to establish the AS model and evaluate the therapeutic effect of AMD on AS. Based on network pharmacology technology, the potential mechanism of AMD for treating AS was explored, and lipid metabolism pathways related to AS were mainly studied. Next, the effects of AMD on liver lipid levels, antioxidant capacity, liver tissue morphology, and gene expression related to lipid metabolism in ApoE-/- mice were investigated. Cellular experiments were performed to confirm the lipid-lowering effect of AMD. Finally, the AMD composition was determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Results: In ApoE-/- mice, AMD effectively alleviated AS by reducing serum total cholesterol, triglyceride, low-density lipoprotein levels, and plaque area, and increasing high-density lipoprotein levels. Network pharmacology indicated that AMD may suppress AS by regulating lipid metabolism pathways with multiple TCM components, which is consistent with the results of in vivo experiments and LC-MS/MS component identification. AMD significantly reduced liver lipid aggregation, intensified antioxidant enzyme activity, and upregulated the mRNA levels of ABCA1, ABCG1, and LDLR with increased cholesterol efflux. In addition, AMD decreased cholesterol levels in foam cells.

Conclusions: This study confirmed that AMD could treat AS by regulating lipid metabolism and preliminarily explored the related mechanism. These findings provide new ideas for the treatment of AS with TCM.

Keywords: Anmeidan; Atherosclerosis; LC-MS/MS; cholesterol.; lipid metabolism; network pharmacology.